Could a common diabetes pill ease long COVID?
NCT ID NCT06907251
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This Phase 3 trial tests whether dapagliflozin, a drug used for diabetes, can improve quality of life in people with long COVID. 192 adults with persistent symptoms for at least 12 weeks after a COVID infection will receive either the drug or a placebo daily for 12 months. The main goal is to see if the drug helps with overall well-being and reduces complications like diabetes or heart problems.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dapagliflozin (a diabetes drug taken as a pill once daily)
What this could lead to
If it works, this could offer a simple, daily pill to help manage long COVID symptoms and improve quality of life.
What could go wrong
This is a relatively small Phase 3 trial. Dapagliflozin is a diabetes drug, and its benefits for long COVID are unproven. It may not work for everyone and could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Ottawa Heart Institute
Ottawa, Ontario, K1Y 4W7, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••